Synthesis of Aspergillomarasmine A and Toxin A Hydroxamic Acid Derivatives for Evaluation as Metallo-β-Lactamase Inhibitors
ACS Infectious Diseases · 29.10.2026
DOI: 10.1021/acsinfecdis.6c00636 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 29.10.2026. Verfasst von Jack K Bradley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Liverpool, LiverpoolL69 7ZD, U.K. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Hydroxamic Acids, Anti-Bacterial Agents. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council (EPSRC), UK Research and Innovation (UKRI).
Abstract (Originalsprache)
Resistance to β-lactam antibiotics in Gram-negative bacteria is identified by the World Health Organization as a major threat to global health. Such resistance is increasingly mediated by serine- and metallo-β-lactamases, that catalyze beta-lactam hydrolysis. While serine-β-lactamase inhibitors are widely used in combination therapies, there is a lack of clinically approved metallo-β-lactamase inhibitors, although several promising candidates have been identified. Among these, the fungal natural product aspergillomarasmine A (AMA) inhibits metallo-β-lactamases including New Delhi metallo-β-lactamase-1 (NDM-1), restoring the activity of meropenem against resistant isolates. Here, we report robust and scalable routes for the synthesis of AMA and toxin A, enabling selective modifications to be made at each carboxylic acid of the AMA scaffold. Seven hydroxamic acid derivatives were synthesized in addition to cyclic derivatives of AMA and toxin A. The inhibition activities (pIC50 values) of the compounds were evaluated against a range of isolated clinically relevant metallo-β-lactamases, including in the presence of different Zn(II) concentrations. Microbiological assays were performed, with AMA, toxin A, and their hydroxamic acid derivatives restoring the activity of meropenem against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii strains, obtained from clinical and environmental isolates from Tanzania and Malawi, containing NDM-1 or NDM-5. The synthetic procedures and metallo-β-lactamase inhibition results described will promote and enable further optimization of metallo-β-lactamase inhibitors based on the AMA scaffold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Liverpool, LiverpoolL69 7ZD, U.K.
- Centre for Drugs and Diagnostics, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, LiverpoolL3 5QA, U.K.
- Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, Chemistry Research Laboratory, University of Oxford, 12, Mansfield Road, OxfordOX1 3TA, U.K.
- School of Pharmacy and Food Engineering, Wuyi University, Jiangmen529020, P.R. China.
ORCID-Profile: Christopher J Schofield, W David Hong
Förderung
- Engineering and Physical Sciences Research Council (EPSRC)
- UK Research and Innovation (UKRI)
Zitieren
APA
Bradley, J. K., Calvopiña, K., Lee, Y., Gao, M., Ackers-Johnson, G., Wu, P., Schofield, C. J., Roberts, A. P., & Hong, W. D. (2026). Synthesis of Aspergillomarasmine A and Toxin A Hydroxamic Acid Derivatives for Evaluation as Metallo-β-Lactamase Inhibitors. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.6c00636
Vancouver
Bradley JK, Calvopiña K, Lee Y, Gao M, Ackers-Johnson G, Wu P, et al. Synthesis of Aspergillomarasmine A and Toxin A Hydroxamic Acid Derivatives for Evaluation as Metallo-β-Lactamase Inhibitors. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.6c00636
BibTeX
@article{Bradley2026,
author = {Bradley, Jack K and Calvopiña, Karina and Lee, Yugyong and Gao, Min and Ackers-Johnson, Gavin and Wu, Panpan and Schofield, Christopher J and Roberts, Adam P and Hong, W David},
title = {Synthesis of Aspergillomarasmine A and Toxin A Hydroxamic Acid Derivatives for Evaluation as Metallo-β-Lactamase Inhibitors},
journal = {ACS Infectious Diseases},
year = {2026},
doi = {10.1021/acsinfecdis.6c00636}
}
EUVIMED